Aeglea BioTherapeutics : Costs Associated with Exit/Disposal - Form 8-K
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to... | April 12, 2023